Investors

Oncopeptides strives to ensure that analysts, investors, shareholders and financial media are provided with correct information to enhance understanding of our operations.

CEO Marty J Duvall summurizes the Year 2020

Our vision is to bring hope to In brief patients through passionate people, innovative science, and transformative medicines.

FDA approval of PEPAXTO - Webcast

In conjunction with the FDA approval of PEPAXTO, Oncopeptides hosted a webcast Monday March 1, 2021, including presentations by CEO Marty J Duvall, CSO Jakob Lindberg, CMO Klaas Bakker, and CFO Anders Martin-Löf. The webcast was recorded. 

More information

Released

Annual Report 2020

“The past year was a transformational year for Oncopeptides  highlighted by the FDA´s priority review of our NDA submission, which paved the way for an accelerated approval in the U.S. in early 2021.”

Marty J Duvall, CEO

 

Click here to watch the film where CEO Marty J Duvall summarizes a transformational year.

 

Annual Report 2020 - online version

 

For further information, please contact:

Linda Holmström
Director of Investor Relations

Profile image

Press release -

Oncopeptides completes patient enrollment in phase 2 PORT study

Read press release
Upcoming events

Upcoming events

View calendar

CEO Marty J Duvall interviewed in Di.TV

CEO Marty J Duvall interviewed by Di.TV

In conjunction with the FDA approval, Oncopeptides' CEO Marty J Duvall was interviewed by the Swedish economy TV channel Di.TV Börsmorgon. See the interview (after about 30 sek the interview turns into English). 

See the interview

Presentations

See our latest Investor presentations To the archive

Webcast - Cowen 41st Annual Health Care Conference

Oncopeptides presents at Cowen 41st Annual Health Care Conference March 3, 2021, at 17:00 (CET).

Read more

Oncopeptides via e-mail

Get our latest updates straight to your inbox. Unsubscribe at anytime.

This site is protected by reCAPTCHA & the Google Privacy Policy & Terms of Service  apply.